PGxAI, a company that uses artificial intelligence (AI) in genetics, has introduced a new tool to help doctors give better treatment to people using weight-loss drugs like Ozempic and Wegovy (both brand names for semaglutide).
How the Tool Works
The AI tool studies a patient’s genetic data to find out if their body may react differently to semaglutide. It shows that about 1 in 3 people may have genes that increase their risk of side effects like:
- Pancreatitis (inflammation of the pancreas)
- Gallbladder issues
- Kidney problems
- Possible thyroid tumors
This means not everyone responds to the drug the same way — and some could be harmed if their genetics aren’t considered.
Making Weight-Loss Treatment Safer
Semaglutide helps people lose weight and manage blood sugar, but it isn’t risk-free. PGxAI’s AI technology helps doctors identify which patients might face serious side effects before they start treatment. It also works with other popular weight-loss drugs, not just semaglutide.
Dr. Mike Zack, PGxAI’s co-founder and CEO, said, “Trying different drugs without checking genetics first isn’t safe anymore. Our AI turns complex genetic data into simple advice for doctors.”
Fast Results, Ready for Clinics
In the past, getting genetic results took weeks. Now, PGxAI’s tool gives results in just minutes. It also connects directly with the systems doctors already use in hospitals, so they don’t need to change how they work.
A Big Step Toward Personalized Medicine
As more people deal with obesity and take GLP-1 drugs like Ozempic, it’s more important than ever to make treatments safer and more effective. Nearly 75% of adults in the U.S. are affected by obesity, and weight-loss drugs are used by millions.
Allan Gobbs, PGxAI’s co-founder, said, “This isn’t just about avoiding bad side effects — it’s about helping millions get the right treatment. One-size-fits-all doesn’t work anymore.”
PGxAI’s new AI report gives doctors a fast, smart way to choose safer, personalized treatments for their patients.
Source: hitconsultant
